Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
Titel:
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
Auteur:
Orlowski, Robert Z. Moreau, Philippe Niesvizky, Ruben Ludwig, Heinz Oriol, Albert Chng, Wee Joo Goldschmidt, Hartmut Yang, Zhao Kimball, Amy S. Dimopoulos, Meletios